 Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 9 | 2 | 11 | | 1996 | 24 | 4 | 28 | | 1997 | 8 | 4 | 12 | | 1998 | 6 | 6 | 12 | | 1999 | 10 | 6 | 16 | | 2000 | 11 | 9 | 20 | | 2001 | 14 | 5 | 19 | | 2002 | 9 | 4 | 13 | | 2003 | 13 | 10 | 23 | | 2004 | 14 | 9 | 23 | | 2005 | 16 | 12 | 28 | | 2006 | 8 | 3 | 11 | | 2007 | 8 | 10 | 18 | | 2008 | 8 | 10 | 18 | | 2009 | 12 | 19 | 31 | | 2010 | 16 | 11 | 27 | | 2011 | 11 | 13 | 24 | | 2012 | 11 | 10 | 21 | | 2013 | 21 | 8 | 29 | | 2014 | 16 | 10 | 26 | | 2015 | 16 | 8 | 24 | | 2016 | 13 | 15 | 28 | | 2017 | 18 | 10 | 28 | | 2018 | 6 | 9 | 15 | | 2019 | 14 | 10 | 24 | | 2020 | 14 | 14 | 28 | | 2021 | 14 | 8 | 22 | | 2022 | 0 | 12 | 12 | | 2023 | 2 | 14 | 16 | | 2024 | 7 | 23 | 30 | | 2025 | 7 | 4 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Almond CS, Daly KP, Albers EL, Alejos JC, Ameduri R, Auerbach SR, Barkoff L, Barnes AP, Bock MJ, Butto A, Carlo WF, Castleberry CD, Chrisant MR, Deshpande SR, Dreyer WJ, Everitt MD, Feingold B, Gonzales S, Hollander SA, Kindel SJ, Klein GL, Lal AK, Lamour JM, Lee J, Lu M, Lytrivi ID, Miyamoto SD, Pahl E, Peng DM, Ryan TD, Singh TP, Su JA, Sutcliffe DL, Ybarra AM, Zangwill S, Rossano JW, Sleeper LA. Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025 Oct 21; 334(15):1339-1348.
-
Gasperetti A, Muller SA, Peretto G, Asatryan B, Protonotarios A, Laredo M, Tarlet PY, Syrris P, Carrick RT, Murray B, Tichnell C, Scheel P, Gigli M, Yap SC, Pilichou K, Basso C, Medo K, Jason M, Rossi VA, Saguner AM, Duru F, Abrams D, Cadrin-Tourigny J, Targetti M, Pieroni M, Graziosi M, Biagini E, Charron P, Cox M, Casella M, Tondo C, Ware JS, Prasad SK, Calò L, Smith E, Ingles J, Tandri H, Ader F, Peters S, Zentner D, Russo J, Ravaro S, Crotti L, Dittmann S, Schulze-Bahr E, Carruth ED, Krysov VA, Parikh VN, Conte G, Wilde A, van Tintelen JP, Te Riele ASJM, Sinagra G, Mestroni L, Taylor M, Merlo M, Adamo L, Calkins H, Bauce B, Arbelo E, Elliott PM, Gandjbakhch E, Lakdawala N, Helms A, James CA, Gilotra NA. Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. Circulation. 2025 Oct 07; 152(14):978-989.
-
Shimamura A, Maschan A, Bennett C, Samarasinghe S, Farrar JE, Li CK, Sirachainan N, Pongtanakul B, Komvilaisak P, Zubarovskaya L, Rothman JA, Walkovich K, Nakano TA, Bertuch AA, Ferrao A, Bhat R, Hanna R, Overholt K, Boklan J, Wong TF, Wang Q, Urban P, Strahm B, Wang W, Vlachos A, Williams DA. Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025 Aug 12; 9(15):3728-3738.
-
Shimbo A, Kaneko S, Irabu H, Akutsu Y, Hayashi Y, Mouri M, Yamazaki S, Mori M, Shimizu M. Efficacy of hydroxychloroquine treatment for the skin manifestations of juvenile dermatomyositis. Mod Rheumatol Case Rep. 2025 Jul 25; 9(2).
-
Matson SM, Kim GHJ, Humphries SM, Roth MD, Goldin J, Tashkin DP, Leng M, England BR, Lee JS, Volkmann ER. Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax. 2025 07 15; 80(8):540-546.
-
van Dooren HJ, van Schaik M, Dorjée AL, Arends EJ, Mackay M, Cooney L, Fox DA, Wofsy D, Smilek D, Aranow C, Dall'Era M, Huizinga TWJ, van Kooten C, Toes REM, Diamond B, Teng YKO, Suurmond J. Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell-Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025 Nov; 77(11):1560-1572.
-
Denburg MR, Hirabayashi K, Davies AG, Razzaghi H, Dharnidharka VR, Dixon BP, Flynn JT, Gluck CA, Mitsnefes MM, Smoyer WE, Furth SL, Forrest CB. Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022. Pediatr Nephrol. 2025 Oct; 40(10):3121-3127.
-
Shunyakova J, Patnaik JL, Xia J, Hassman LM, Pecen PE, Palestine AG, Reddy AK. Immunomodulatory Therapy Discontinuation for Reasons Other Than Efficacy in the Treatment of Ocular Inflammation. Ocul Immunol Inflamm. 2025 Oct; 33(8):1807-1810.
-
Ahmed S, Pfeiffer RM, Volesky-Avellaneda K, Blosser CD, Snyder JJ, Israni AK, Lynch CF, Qiao B, Rees JR, Zwald F, Yu KJ, Engels EA. Real-world evidence regarding cancer, mortality, and graft failure risk with de novo belatacept use among kidney transplant recipients in the United States. Am J Transplant. 2025 Aug; 25(8):1723-1734.
-
Raghu VK, Rothenberger SD, Squires JE, Eisenberg E, Peters AL, Halma J, Antala S, Batsis ID, Zhang KY, Feldman AG, Leung DH, Lobritto SJ, Bucuvalas J, Horslen SP, Mazariegos GV, Perito ER. Association Between Early Immunosuppression Center Variability and One-Year Outcomes After Pediatric Liver Transplant. Pediatr Transplant. 2025 Feb; 29(1):e70018.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|